Elizabeth A. Musgrove
#160,735
Most Influential Person Now
Elizabeth A. Musgrove's AcademicInfluence.com Rankings
Elizabeth A. Musgrovephilosophy Degrees
Philosophy
#9257
World Rank
#12791
Historical Rank
Logic
#6244
World Rank
#7745
Historical Rank
Elizabeth A. Musgrovebiology Degrees
Biology
#12712
World Rank
#16207
Historical Rank
Genetics
#1404
World Rank
#1506
Historical Rank
Download Badge
Philosophy Biology
Elizabeth A. Musgrove's Degrees
- PhD Genetics Stanford University
- Bachelors Biology University of California, Berkeley
Similar Degrees You Can Earn
Why Is Elizabeth A. Musgrove Influential?
(Suggest an Edit or Addition)Elizabeth A. Musgrove's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Genomic analyses identify molecular subtypes of pancreatic cancer (2016) (2343)
- Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. (1983) (2078)
- Whole genomes redefine the mutational landscape of pancreatic cancer (2015) (1983)
- Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes (2012) (1752)
- Biological determinants of endocrine resistance in breast cancer (2009) (1199)
- Cyclin D as a therapeutic target in cancer (2011) (1187)
- Expression and amplification of cyclin genes in human breast cancer. (1993) (730)
- Whole-genome landscape of pancreatic neuroendocrine tumours (2017) (616)
- Estrogen-induced Activation of Cdk4 and Cdk2 during G1-S Phase Progression Is Accompanied by Increased Cyclin D1 Expression and Decreased Cyclin-dependent Kinase Inhibitor Association with Cyclin E-Cdk2* (1997) (453)
- Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. (1994) (395)
- Patterns of somatic structural variation in human cancer genomes (2020) (377)
- Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. (2003) (327)
- Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. (1993) (324)
- PI3K pathway activation in breast cancer is associated with the basal‐like phenotype and cancer‐specific mortality (2010) (285)
- Cyclin D1, EMS1 and 11q13 Amplification in Breast Cancer (2003) (275)
- c-Myc or Cyclin D1 Mimics Estrogen Effects on Cyclin E-Cdk2 Activation and Cell Cycle Reentry (1998) (259)
- Cyclins and Breast Cancer (1996) (256)
- Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes (1991) (254)
- Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. (2005) (241)
- Cell cycle control in breast cancer cells (2006) (217)
- Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. (1999) (214)
- Comprehensive molecular characterization of mitochondrial genomes in human cancers (2017) (197)
- Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. (1995) (197)
- Hypermutation In Pancreatic Cancer. (2017) (160)
- Effect of medroxyprogesterone acetate on proliferation and cell cycle kinetics of human mammary carcinoma cells. (1988) (158)
- Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer. (2011) (151)
- Cyclins: Roles in mitogenic signaling and oncogenic transformation (2006) (149)
- A Pure Estrogen Antagonist Inhibits Cyclin E-Cdk2 Activity in MCF-7 Breast Cancer Cells and Induces Accumulation of p130-E2F4 Complexes Characteristic of Quiescence* (2000) (147)
- The nuclear chloride ion channel NCC27 is involved in regulation of the cell cycle (2000) (144)
- Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. (2001) (144)
- Cytoplasmic Localization of β-Catenin is a Marker of Poor Outcome in Breast Cancer Patients (2010) (138)
- Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. (1997) (137)
- Mechanisms of Cyclin-Dependent Kinase Inactivation by Progestins (1998) (135)
- Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. (2013) (134)
- Increased Proliferation and Altered Growth Factor Dependence of Human Mammary Epithelial Cells Overexpressing the Gab2 Docking Protein* (2006) (129)
- INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. (2000) (129)
- Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells. (2002) (128)
- Ploidy as a Prognostic Factor in Ovarian Cancer (1983) (125)
- Dysregulation of Hedgehog, Wnt and Notch signalling pathways in breast cancer. (2009) (125)
- Estrogen and Progestin Regulation of Cell Cycle Progression (2004) (125)
- Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells (2012) (124)
- Distinct and redundant functions of cyclin E1 and cyclin E2 in development and cancer (2010) (120)
- Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models (2001) (119)
- Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells (2014) (116)
- Flow cytometric measurement of cytoplasmic pH: a critical evaluation of available fluorochromes. (1986) (114)
- Points of action of estrogen antagonists and a calmodulin antagonist within the MCF-7 human breast cancer cell cycle. (1989) (113)
- Deregulated Cyclin D1 Expression Is Associated with Decreased Efficacy of the Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cell Lines (2004) (112)
- Ribonucleotide reductase M1 subunit in cellular proliferation, quiescence, and differentiation. (1988) (108)
- EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer (1997) (106)
- Clinical and molecular characterization of HER2 amplified-pancreatic cancer (2013) (105)
- Expression of the PEA3 group of ETS‐related transcription factors in human breast‐cancer cells (1997) (103)
- DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer (2015) (99)
- Identification of Functional Networks of Estrogen- and c-Myc-Responsive Genes and Their Relationship to Response to Tamoxifen Therapy in Breast Cancer (2008) (98)
- Meta-Analysis and Gene Set Enrichment Relative to ER Status Reveal Elevated Activity of MYC and E2F in the “Basal” Breast Cancer Subgroup (2009) (95)
- Relationship between cytoplasmic pH and proliferation during exponential growth and cellular quiescence. (1987) (93)
- Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib. (2007) (93)
- Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens. (2002) (88)
- Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells (2004) (88)
- Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells (1998) (87)
- EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival (1998) (86)
- Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome (2009) (82)
- Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer. (2009) (81)
- Involvement of RB-1, p53, p16INK4 and telomerase in immortalisation of human cells. (1995) (80)
- Cell cycle proteins in epithelial cell differentiation: Implications for breast cancer (2010) (80)
- Expression of the cyclin‐dependent kinase inhibitors p16INK4, p15INK4B and p21Waf1/cip1 in human breast cancer (1995) (78)
- c-Myc overexpression and endocrine resistance in breast cancer (2006) (73)
- Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer. (1996) (73)
- Inhibition of the MAP kinase cascade blocks heregulin-induced cell cycle progression in T-47D human breast cancer cells (1998) (72)
- Regulation of cyclin expression and cell cycle progression in breast epithelial cells by the helix–loop–helix protein Id1 (2005) (70)
- Cell cycle machinery: links with genesis and treatment of breast cancer. (2008) (69)
- Differential effects of retinoids and antiestrogens on cell cycle progression and cell cycle regulatory genes in human breast cancer cells. (1996) (68)
- Antiprogestin inhibition of cell cycle progression in T-47D breast cancer cells is accompanied by induction of the cyclin-dependent kinase inhibitor p21. (1997) (68)
- The E3 Ubiquitin Ligase EDD Regulates S-Phase and G2/M DNA Damage Checkpoints (2007) (65)
- Estrogen Regulation of Cyclin E2 Requires Cyclin D1 but Not c-Myc (2009) (65)
- High Notch1 protein expression is an early event in breast cancer development and is associated with the HER‐2 molecular subtype (2010) (63)
- The influence of age on the DNA ploidy levels of breast tumours. (1983) (63)
- Effects of 1,25‐dihydroxyvitamin D3 on cell‐cycle kinetics of T 47D human breast cancer cells (1989) (61)
- Measurement of intracellular pH. (1990) (60)
- HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer (2020) (60)
- Inhibitors of cell cycle kinases: recent advances and future prospects as cancer therapeutics. (2012) (60)
- Cooperation of p27Kip1 and p18INK4c in Progestin-Mediated Cell Cycle Arrest in T-47D Breast Cancer Cells (2000) (60)
- Cyclins and breast cancer (2005) (59)
- Retinoic Acid-mediated Growth Arrest Requires Ubiquitylation and Degradation of the F-box Protein Skp2* (2001) (58)
- Cell cycle control by steroid hormones. (1994) (58)
- Tamoxifen-Induced Epigenetic Silencing of Oestrogen-Regulated Genes in Anti-Hormone Resistant Breast Cancer (2012) (58)
- Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer (2019) (57)
- Cyclin D1 Overexpression Induces Progestin Resistance in T-47D Breast Cancer Cells Despite p27Kip1 Association with Cyclin E-Cdk2* (2001) (57)
- Transferrin receptor expression during exponential and plateau phase growth of human tumour cells in culture (1984) (56)
- Clinical and pathologic features of familial pancreatic cancer (2014) (55)
- Cyclin D2 activates Cdk2 in preference to Cdk4 in human breast epithelial cells (1997) (54)
- CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease (2009) (53)
- Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX (2012) (53)
- Recruitment and Activation of Pancreatic Stellate Cells from the Bone Marrow in Pancreatic Cancer: A Model of Tumor-Host Interaction (2011) (53)
- BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer (2013) (49)
- Regulation of cell proliferation by ERK and signal-dependent nuclear translocation of ERK is dependent on Tm5NM1-containing actin filaments (2015) (48)
- Cyclin gene expression and growth control in normal and neoplastic human breast epithelium (1993) (46)
- Global characterization of signalling networks associated with tamoxifen resistance in breast cancer (2013) (44)
- BAG-1 predicts patient outcome and tamoxifen responsiveness in ER-positive invasive ductal carcinoma of the breast (2008) (43)
- DNA flow cytometry of paraffin-embedded tissue. (1984) (42)
- Immunofluorescent quantification of ribonucleotide reductase M1 subunit and correlation with DNA content by flow cytometry. (1987) (42)
- Inducible expression of cyclin D1 in T‐47D human breast cancer cells is sufficient for Cdk2 activation and pRB hyperphosphorylation (1996) (42)
- Cyclin E2 induces genomic instability by mechanisms distinct from cyclin E1 (2013) (41)
- Sex differences in oncogenic mutational processes (2019) (41)
- Regulation of breast cancer cell cycle progression by growth factors, steroids and steroid antagonists (1992) (40)
- p27Kip1 Induces Quiescence and Growth Factor Insensitivity in Tamoxifen-treated Breast Cancer Cells (2003) (40)
- Wnt signalling via the epidermal growth factor receptor: a role in breast cancer? (2003) (38)
- Progestins reinitiate cell cycle progression in antiestrogen-arrested breast cancer cells through the B-isoform of progesterone receptor. (2007) (38)
- Overexpression of E2F-1 is associated with increased disease-free survival in squamous cell carcinoma of the anterior tongue. (2003) (37)
- Steroids, growth factors, and cell cycle controls in breast cancer. (1991) (37)
- Acute effects of growth factors on T-47D breast cancer cell cycle progression. (1993) (36)
- The NSAID sulindac is chemopreventive in the mouse distal colon but carcinogenic in the proximal colon (2010) (36)
- Precision Oncology in Surgery: Patient Selection for Operable Pancreatic Cancer. (2020) (35)
- Modulation of the growth-inhibitory effects of progestins and the antiestrogen hydroxyclomiphene on human breast cancer cells by epidermal growth factor and insulin. (1989) (35)
- Expression and regulation of cyclin genes in breast cancer. (1995) (33)
- Wilms' tumor protein 1: an early target of progestin regulation in T-47D breast cancer cells that modulates proliferation and differentiation (2008) (32)
- p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells. (2003) (31)
- Cortactin Modulates RhoA Activation and Expression of Cip/Kip Cyclin-Dependent Kinase Inhibitors To Promote Cell Cycle Progression in 11q13-Amplified Head and Neck Squamous Cell Carcinoma Cells (2010) (31)
- The estrogen and c-Myc target gene HSPC111 is over-expressed in breast cancer and associated with poor patient outcome (2008) (31)
- Cooperation of p27(Kip1) and p18(INK4c) in progestin-mediated cell cycle arrest in T-47D breast cancer cells. (2000) (30)
- The helix-loop-helix protein Id1 requires cyclin D1 to promote the proliferation of mammary epithelial cell acini. (2008) (30)
- p14ARF Protein Expression Is a Predictor of Both Relapse and Survival in Squamous Cell Carcinoma of the Anterior Tongue (2005) (30)
- Role of the CDK Inhibitor p27 (Kip1) in Mammary Development and Carcinogenesis: Insights from Knockout Mice (2004) (29)
- Cyclin E Expression and Outcome in Pancreatic Ductal Adenocarcinoma (2006) (29)
- PI3K Pathway Activation in Breast Cancer Is Associated with the Basal-Like Phenotype and Cancer-Specific Mortality. (2009) (28)
- Differences in degradation lead to asynchronous expression of cyclin E1 and cyclin E2 in cancer cells (2013) (27)
- Hormonal regulation of the Grb14 signal modulator and its role in cell cycle progression of MCF‐7 human breast cancer cells (2005) (27)
- The PDZ-binding motif of MCC is phosphorylated at position -1 and controls lamellipodia formation in colon epithelial cells. (2012) (27)
- Effects of the progestin antagonist RU 486 on T-47D breast cancer cell cycle kinetics and cell cycle regulatory genes. (1993) (27)
- Identification of PUMA as an estrogen target gene that mediates the apoptotic response to tamoxifen in human breast cancer cells and predicts patient outcome and tamoxifen responsiveness in breast cancer (2011) (27)
- The cyclin-dependent kinase inhibitor p27 (Kip1) regulates both DNA synthesis and apoptosis in mammary epithelium but is not required for its functional development during pregnancy. (2003) (24)
- Sulindac activates NF-κB signaling in colon cancer cells (2013) (23)
- Deregulated Cyclin D 1 Expression Is Associated with Decreased Efficacy of the Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cell Lines (2004) (23)
- Mutated in colorectal cancer protein modulates the NFκB pathway. (2012) (22)
- Modulation of transferrin receptor expression by inhibitors of nucleic acid synthesis (1985) (22)
- Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (22)
- Cyclin E2 is the predominant E-cyclin associated with NPAT in breast cancer cells (2015) (21)
- The "Mutated in Colorectal Cancer" Protein Is a Novel Target of the UV-Induced DNA Damage Checkpoint. (2010) (20)
- Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status (2010) (19)
- The surface expression of a tumor‐associated antigen on human kappa myeloma cells (1984) (19)
- Cyclin E and prognosis in patients with breast cancer. (2002) (18)
- Overexpression of Cyclin D 1 Messenger RNA Predicts for Poor Prognosis in Estrogen Receptor-positive Breast Cancer 1 (1999) (18)
- Live or let die: oestrogen regulation of survival signalling in endocrine response (2007) (17)
- Differential effects of phorbol ester on epidermal growth factor receptors in estrogen receptor-positive and -negative breast cancer cell lines. (1990) (17)
- INK 4 a Gene Expression and Methylation in Primary Breast Cancer : Overexpression of p 16 INK 4 a Messenger RNA Is a Marker of Poor Prognosis 1 (2000) (16)
- Retinoid Signaling in Pancreatic Cancer, Injury and Regeneration (2011) (16)
- The antiproliferative effects of progestins in T47D breast cancer cells are tempered by progestin induction of the ETS transcription factor Elf5. (2010) (15)
- The epigenetic agents suberoylanilide hydroxamic acid and 5‑AZA‑2' deoxycytidine decrease cell proliferation, induce cell death and delay the growth of MiaPaCa2 pancreatic cancer cells in vivo. (2015) (14)
- HUMAN MYELOID DIFFERENTIATION ANTIGENS IDENTIFIED BY MONOCLONAL ANTIBODIES: EXPRESSION ON LEUKEMIC CELLS (1985) (14)
- Identification of downstream targets of estrogen and c-myc in breast cancer cells. (2008) (14)
- Role of endoplasmic reticulum stress induction by the plant toxin, persin, in overcoming resistance to the apoptotic effects of tamoxifen in human breast cancer cells (2013) (13)
- Cooperation of p 27 Kip 1 and p 18 INK 4 c in Progestin-Mediated Cell Cycle Arrest in T-47 D Breast Cancer Cells (2000) (13)
- Cyclins and breast cancer. (1996) (13)
- 42. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality (2011) (13)
- Steroidal regulation of cell cycle progression. (2007) (12)
- Different points of action of retinoids and anti‐estrogens in G1 phase identified in synchronized T‐47D breast cancer cells (1997) (12)
- LMO4 expression in squamous cell carcinoma of the anterior tongue (2011) (10)
- Cell cycle control by steroid hormones in breast cancer: implications for endocrine resistance (1995) (10)
- Precision Oncology in Surgery (2018) (9)
- Flow cytometric enumeration of drug-resistant tumor cells. (1988) (8)
- Estrogen receptor degradation: a CUE for endocrine resistance? (2011) (7)
- EXPRESSION OF S100A2 CALCIUM-BINDING PROTEIN PREDICTS RESPONSE TO PANCREATECTOMY FOR PANCREATIC CANCER (2008) (7)
- RB in breast cancer (2010) (7)
- Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours (2017) (6)
- Cyclin-dependent kinases as downstream targets of oestrogen action: potential prognostic indicators and therapeutic targets (1997) (6)
- Aberrent hedgehog signaling is an early event in breast cancer development. (2009) (6)
- International Congress on Hormonal Steroids and Hormones and Cancer Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells (2003) (6)
- Hormonal Control of Breast Cancer Cell Cycle Progression (1994) (6)
- Estrogen Regulation of Cell Cycle Progression (2001) (5)
- Human Cell Culture (2002) (4)
- Enumeration of 6-thioguanine-resistant tumour cells using flow cytometry and comparison with a microtitration cloning assay. (1989) (4)
- 29. c-MYC gene amplification is associated with a poor prognosis in invasive ductal carcinoma (2010) (3)
- Endocrine therapy: defining the path of least resistance (2014) (3)
- T-47D Breast Cancer Cells Progestin-Mediated Cell Cycle Arrest in in INK4c and p18 Kip1 Cooperation of p27 (2014) (3)
- Transferrin receptor cycling by human lymphoid cells: lack of effect from inhibition of microtubule assembly. (1986) (2)
- Clinical utility of molecular profiling using EUS-guided Biopsies in Pancreatic cancer: The PRECISION-Panc experience (2018) (2)
- Progestin Regulation of Cell Proliferation in the Breast and Endometrium (1995) (2)
- Antiestrogens and the Cell Cycle (2009) (1)
- Sulindac activates NF-κB signaling in colon cancer cells (2013) (1)
- Review of: c-Myc suppresses p21 WAF1/CIP1 expression during oestrogen signalling and antioestrogen resistance in human breast cancer cells (2006) (1)
- Endocrine-Related Cancer ( 2003 ) 10 179 – 186 International Congress on Hormonal Steroids and Hormones and Cancer Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells (2003) (1)
- Estrogens, Cell Proliferation and Breast Cancer (2008) (1)
- Chapter 4 Progestin regulation of cellular proliferation (1996) (1)
- Author Correction: Pan-cancer analysis of whole genomes (2023) (1)
- Endocrine therapy: defining the path of least resistance (2014) (1)
- Use of the novel biomarker (HOXB2) to predict response to pancreatectomy for pancreatic cancer (2007) (1)
- Patient Selection for Operable Pancreatic Cancer (2020) (1)
- 314 The Novel Biomarker (HOXB2) Predicts Response to Pancreatectomy for Pancreatic Cancer (2008) (1)
- Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX (2012) (1)
- Clinical and molecular characterization of HER2amplified-pancreatic cancer (2013) (1)
- Author Correction: Inferring structural variant cancer cell fraction (2022) (0)
- Mechanisms of Anti-Estrogen and Retinoid Inhibition of Breast Cancer Cell Proliferation (1996) (0)
- Cyclin E2 is the predominant E-cyclin associated with NPAT in breast cancer cells (2015) (0)
- Robert Lyndsay Sutherland 1947–2012 (2016) (0)
- 3517 POSTER The novel biomarker (HOXB2) predicts response to pancreatectomy for pancreatic cancer (2007) (0)
- 04 WHOLE GENOME SEQUENCING INFORMS THERAPEUTIC SELECTION FOR PANCREATIC CANCER (2014) (0)
- Inactivation by Progestins Mechanisms of Cyclin-Dependent Kinase (1997) (0)
- Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells (2014) (0)
- Cells by Epidermal Growth Factor and Insulin the Antiestrogen Hydroxyclomiphene on Human Breast Cancer Modulation of the Growth-inhibitory Effects of Progestins and Updated Version (2006) (0)
- 8. Cyc1ins and breast cancer (1996) (0)
- Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression (1993) (0)
- 97. Steroid regulation of breast cancer cell proliferation (2003) (0)
- Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (0)
- Intrinsic subtype and its clinical significance in early node-negative breast cancer: Results from two randomized trials of adjuvant chemoendocrine therapy. (2012) (0)
- Abstract 1156: A molecular pre-operative prognostic nomogram for resectable pancreatic cancer. (2012) (0)
- Author Correction: Patterns of somatic structural variation in human cancer genomes (2020) (0)
- Mechanisms underlying uncontrolled genome doubling in breast cancer (2019) (0)
- Estrogen/Estrogen Antagonist Regulation of the Cell Cycle in Breast Cancer Cells (2002) (0)
- 41. Differences in cell cycle and apoptotic biomarker expression between molecular subtypes of invasive ductal breast carcinoma (2011) (0)
- Preface: The Cell Cycle (2004) (0)
- Progestins BothStimulate andInhibit Breast Cancer CellCycle Progression while Increasing Expression ofTransforming GrowthFactor ox,Epidermal GrowthFactor Receptor, c-fos, andc-myc Genes (1991) (0)
- Steroid and steroid antagonist regulation of cyclin D1 and c-myc gene expression in T-47D breast cancer cells (1993) (0)
- Companion Diagnostics and Biomarkers BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer (2013) (0)
- Author Correction: The evolutionary history of 2,658 cancers (2023) (0)
- 40. Cytoplasmic localisation of β catenin is a marker of poor outcome in breast cancer patients (2011) (0)
- Role of Cyclin D1 and p27 in Steroidal Control of Cell Cycle Progression in the Mammary Gland in Vivo (2001) (0)
- 2 Antiestrogens and the Cell Cycle (2019) (0)
- Review of: Short term cyclin D1 overexpression induces centrosome amplification, mitotic spindle abnormalities, and aneuploidy (2005) (0)
- Advances in Brief p 27 Kip 1 Induces Quiescence and Growth Factor Insensitivity in Tamoxifen-treated Breast Cancer Cells 1 (2003) (0)
- Abstracts presented at the 37th Annual Scientific Meeting, 16‐19 May 2004, Sydney, New South Wales (2004) (0)
- ARFProtein Expression Is a Predictorof BothRelapse andSurvival in Squamous Cell Carcinoma of theAnterior Tongue (2005) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Elizabeth A. Musgrove?
Elizabeth A. Musgrove is affiliated with the following schools:
